Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT00629187
What this trial is testing

Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

Who this might be right for
Central Nervous System NeoplasmsNeoplasm Metastasis
Tufts Medical Center 2
Early research (Phase 1)Study completedNCT05628883
What this trial is testing

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Who this might be right for
Metastatic MelanomaUnresectable MelanomaAcral Melanoma+7 more
H. Lee Moffitt Cancer Center and Research Institute 17
Testing effectiveness (Phase 2)Study completedNCT05061017
What this trial is testing

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

Who this might be right for
NSCLCMetastatic Colorectal CarcinomaRefractory Melanoma
Diwakar Davar 13
Testing effectiveness (Phase 2)Looking for participantsNCT05144698
What this trial is testing

RAPA-201 Therapy of Solid Tumors

Who this might be right for
Solid TumorSmall Cell and Non-small Cell Lung CancerHead and Neck Cancer+6 more
Rapa Therapeutics LLC 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07477548
What this trial is testing

Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Who this might be right for
Vascular MalformationsArteriovenous MalformationsVenous Malformation+4 more
Yonsei University 67
Testing effectiveness (Phase 2)WithdrawnNCT05561491
What this trial is testing

ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

Who this might be right for
Melanoma
Targovax Oy
Testing effectiveness (Phase 2)Study completedNCT04305041
What this trial is testing

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 100
Testing effectiveness (Phase 2)Study completedNCT03278665
What this trial is testing

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Who this might be right for
Malignant Melanoma
4SC AG 40
Early research (Phase 1)Looking for participantsNCT06910657
What this trial is testing

IDOV-Immune for Advanced Solid Tumors

Who this might be right for
Colorectal CancerPancreatic CancerMelanoma+13 more
ViroMissile, Inc. 78
Testing effectiveness (Phase 2)Ended earlyNCT01216657
What this trial is testing

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Who this might be right for
Chemo-refractory Melanoma
Krankenhaus Nordwest 7
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Early research (Phase 1)Study completedNCT00101270
What this trial is testing

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

Who this might be right for
Childhood Burkitt LymphomaChildhood Central Nervous System Germ Cell TumorChildhood Diffuse Large Cell Lymphoma+26 more
National Cancer Institute (NCI) 24
Early research (Phase 1)Looking for participantsNCT05039801
What this trial is testing

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Malignant Solid Neoplasm+35 more
M.D. Anderson Cancer Center 54
Testing effectiveness (Phase 2)Looking for participantsNCT05136196
What this trial is testing

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+22 more
National Cancer Institute (NCI)
Early research (Phase 1)Ended earlyNCT02668770
What this trial is testing

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Who this might be right for
Advanced CancersMelanoma
M.D. Anderson Cancer Center 28
Early research (Phase 1)Study completedNCT01021059
What this trial is testing

A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer

Who this might be right for
MelanomaCarcinoma, Renal Cell
National Cancer Institute (NCI) 18
Testing effectiveness (Phase 2)Study completedNCT00509288
What this trial is testing

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Who this might be right for
MelanomaSkin Cancer
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439292
What this trial is testing

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)Ended earlyNCT02459067
What this trial is testing

ImmuniCell® in Patients With Advanced Cancers

Who this might be right for
Malignant MelanomaNon-small Cell Lung CancerRenal Cell Cancer
TC Biopharm 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT06521567
What this trial is testing

Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Who this might be right for
MelanomaHodgkin LymphomaHigh and Low Grade Glioma+9 more
GlaxoSmithKline 83
Next Page
150